Af­ter an odyssey of set­backs, FDA fi­nal­ly green-lights Newron’s Parkin­son’s drug Xada­go

For Italy’s Newron, per­sis­tence has fi­nal­ly paid off. Af­ter fol­low­ing two rad­i­cal­ly dif­fer­ent paths to get its add-on ther­a­py sa­fi­namide on the mar­ket in Eu­rope …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER